Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.50 |
| ▸ | WNT3A | P56704 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036725 | 1.00 | PTPN1 (0.58) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL13990159 | 0.84 | L3MBTL1 (0.52) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL3121320 | 0.83 | ALDH1A1 (0.57) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL31599609 | 0.83 | CES2 (0.61) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL633282 | 0.83 | CES2 (0.61) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL30089515 | 0.82 | CTNNB1 (0.68) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL20508992 | 0.82 | PTPN1 (0.74) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL4598039 | 0.82 | ALB (0.60) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL6757360 | 0.80 | HDAC3 (0.55) | PTPN1ERCC5FEN1CES2CES1 | |
| SCHEMBL5158700 | 0.80 | RXFP1 (0.44) | PTPN1ERCC5FEN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109311907-A | Preparation method of high-purity prasugrel | 吉瑞工厂 | 2019-02-05 | — | — | CN | claimed |
| CN-107722146-A | Method for producing solid polyaluminoxane composition | 三井化学株式会社 | 2018-02-23 | — | — | CN | claimed |
| CN-105801550-A | Novel benzopyran kinase modulators | 理森制药股份公司 | 2016-07-27 | — | — | CN | claimed |
| CN-102976954-B | Preparation method of chiral 2-fluoromethyl phenyl ethylamine | SHANGHAI WUXI APPTEC CO LTD | 2015-04-01 | — | — | CN | claimed |
| CN-103524530-A | Prasugrel hydrobromide and preparation method thereof | GUANGDONG BANGMIN PHARMACEUTICAL CO LTD | 2014-01-22 | — | — | CN | claimed |
| CN-102976954-A | Preparation method of chiral 2-fluoromethyl phenyl ethylamine | WUXI APPTEC CO LTD | 2013-03-20 | — | — | CN | claimed |
| CN-102976953-A | Preparation method of chiral alpha-difluoromethyl phenyl ethylamine | WUXI APPTEC CO LTD | 2013-03-20 | — | — | CN | claimed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| WO-2025076455-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | Escient Pharmaceuticals Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-1994024098-A1 | Ξ-FLUOROSULPHONIMIDES, METHOD OF PREPARING THEM AND THEIR USE AS FLUORINATION AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-10-27 | — | — | WO | disclosed |
| US-5254732-A | N-fluorosulfonimides and their application as fluorinating agents | ALLIED-SIGNAL INC. (US) | 1993-10-19 | — | — | US | disclosed |
| US-5103022-A | Reacting dl-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino -1-propanone with l-acetylphenylglycine to form corresponding diastereomeric salt, deposition, isolation of l-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5057535-A | Muscle relaxants | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-10-15 | — | — | US | disclosed |
| EP-0349358-A1 | Process for presulfiding and controlling the activity of a hydrocarbon treatment catalyst | EURECAT EUROPEENNE DE RETRAITEMENT DE CATALYSEURS (FR) | 1990-01-03 | — | — | EP | disclosed |
| US-4690931-A | IN TREATMENT OF ANOXIA OR BRAIN DAMAGE | SYNTHELABO (FR) | 1987-09-01 | — | — | US | disclosed |
| EP-0200942-A2 | New derivatives of an aminoketone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | PTPN1 885/4885ERCC5 3636/4885FEN1 4316/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | PTPN1 695/4885ERCC5 3364/4885FEN1 4444/4885 |
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | MRGPRX2, MRGPRX1, MRGPRX4 | PTPN1 3236/4885ERCC5 3931/4885FEN1 4743/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | PTPN1 60/4885ERCC5 2658/4885FEN1 1440/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | PTPN1 1013/4885ERCC5 4095/4885FEN1 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.